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The major sphingolipid metabolite, sphingosine-1-phosphate
(S1P), has important biological functions. S1P is the ligand for
a family of five G-protein-coupled receptors with distinct
signaling pathways that regulate angiogenesis, vascular
maturation, immunity, chemotaxis, and other important
biological pathways. Recently, clinical trials have targeted
S1P receptors (S1PRs) for autoimmune diseases and
transplantation and have generated considerable interest
in developing additional, more selective compounds. This
review summarizes current knowledge on the biology of S1P
and S1PRs that forms the basis for future drug development
and the treatment of kidney disease.
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Sphingolipid metabolites are emerging as important lipid
signaling molecules in health and disease.1–3 Among them,
sphingosine-1-phosphate (S1P) is known to play important
roles in cellular processes. S1P, found at concentrations of
0.1–1 mM in human serum, is produced by phosphorylation of
sphingosine by sphingosine kinases (SPHKs) in response to a
variety of stimuli. S1P regulates diverse biological processes
and functions, including cell growth, cell proliferation, and
angiogenesis, and can inhibit apoptosis and lymphocyte
trafficking.4–9 S1P was once considered simply as a break-
down product of ceramide. However, the evolutionally
conserved function of S1P from plants to higher organisms
has highlighted its importance as a pivotal signaling
molecule in normal function and pathophysiology. In
addition, the discovery that S1P is a ligand for specific
receptors (S1P15, formerly endothelial differentiation gene
(EDG)1, -5, -3, -6, -8) has expanded its role as a mediator of
diverse physiologic and pathologic conditions.
SPHINGOLIPID RHEOSTAT AND CELL FATE
Although S1P induces cell growth and proliferation and/or
inhibits apoptosis, two S1P precursors, ceramide and
sphingosine, induce cell cycle arrest and cell death.10–13
Proapoptotic ceramide is formed by activation of sphingo-
myelinase or through the de novo sphingolipid biosynthetic
pathway starting with serine palmitoyl transferase14–16
(Figure 1). Different apoptotic stimuli such as endotoxin,
interleukin-1 (IL-1), or tumor necrosis factor-a can activate
these enzymes,18 whereas other stimuli such as growth
factors, lipopolysaccharide, hypoxia, or IL-1b can activate
SPHK.19,20 Activation of SPHK results in an increase in
S1P levels and inhibition of ceramide-induced apoptosis.
However, S1P is also converted into sphingosine by
sphingosine-1-phosphate phosphatase (SPP), which may
induce apoptosis by itself or by increasing proapoptotic
ceramide synthesis.21–24 Because these sphingolipid metabo-
lites have opposite actions on cell fate, the concept of a
‘sphingolipid rheostat’ has been developed that addresses
the importance of balance of these mediators and not the
absolute amount of metabolites in determining the ultimate
cell fate.25
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S1P SYNTHESIS AND DEGRADATION
Intracellular S1P level is tightly regulated by a balance
between its synthesis by SPHK and degradation by
endoplasmic reticulum SPP (reversible) or S1P lyase
(irreversible).25 By downstream phosphorylation, growth
factors and cytokines can activate SPHK, which mediates
phosphorylation of sphingosine, producing S1P. Two iso-
forms of SPHK, known as SPHK1 and SPHK2, have been
characterized.26,27 Despite similar amino-acid sequences, they
have different kinetics of expression during development28 as
well as different subcellular localization,29,30 suggesting that
these two isoforms serve different functions. Overexpression
of SPHK1 improves cell survival from apoptosis by inhibiting
the activation of caspases and stress-activated protein
kinases.29,31 SPHK1 activation promotes cell proliferation29,32
and regulates cell transformation mediated by Ras activa-
tion.31 In contrast, much less is known about the role of
SPHK2, although several reports suggest that it has
proapoptotic functions.33,34 However, a possibility that the
function of the two isoenzymes in vivo is complementary has
been suggested by the finding that SPHK1/SPHK2 double
knockout mice are embryonic lethal, because of a severe
defect in angiogenesis and neural tube formation, with
almost no detectable level of S1P. In contrast, mice with a
single knockout of either isoenzyme do not display an
abnormal phenotype.6 SPHK2 also phosphorylates and
activates FTY720, a strong immune modulatory drug
currently in clinical trials,35 which, in its phosphorylated
form, is an agonist at S1P1 receptors.
S1P can be degraded reversibly by an S1P-selective
phosphatase (SPP) to produce sphingosine or by S1P lyase
to form hexadecenal and phosphoethanolamine.21,22,36 Two
mammalian SPPs have been recently described.21,22 SPPs
regulate the dynamic balance between various sphingolipid
mediators and ultimately cell fate by mediating depho-
sphorylation of S1P to sphingosine. The irreversible pathway
of S1P degradation depends on S1P lyase, a pyridoxal-
dependent enzyme that cleaves the C2–3 bond of S1P.36,37 S1P
lyase can potentiate apoptosis in response to DNA damage by
the p53 and mitogen-activated protein kinase pathway in
HEK-293 cells.38
S1P RECEPTORS
The first hint that the biological functions of S1P were
receptor mediated came with the discovery of five orphan G-
protein-coupled receptors, originally named the endothelial
differentiation gene (EDG).39–43 Five high-affinity S1P
receptors (S1PRs), EDG1/S1P1, EDG5/S1P2, EDG3/S1P3,
EDG6/S1P4, and EDG8/S1P5, have been characterized
(Figure 2). Each of these S1PRs couples to heterodimeric
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Figure 1 | Sphingosine-1-phosphate (S1P) biosynthetic pathway. The production of S1P can lead to intracellular or extracellular actions.
Extracellular actions are mediated by S1P1–5 receptors in an autocrine or paracrine manner. Adapted from Alvarez et al.
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G-proteins (ai, aq, or a12/13) with subsequent activation
of downstream signaling molecules, such as phospholipase
C/D,44–46 small GTPases,47,48 mitogen-activated protein
kinase,49–51 and Akt.52,53 The diversity of responses mediated
by S1PRs, including immunity, cell migration, angiogenesis,
and heart development, depends on the pattern of receptor
expression and the associated downstream effectors. For
example, activation of S1P1 or S1P3 increases random or
chemotactic migration of endothelial cells (ECs), whereas
binding to S1P2 has an opposite effect.
54–56 The S1PRs can
differentially regulate small GTPases of the Rho family,
particularly Rho and Rac, which are important in cytoskeletal
rearrangement, and produce effects on maintenance/disrup-
tion of cell barrier integrity or cell migration.57,58 S1P
activation of S1P1 mediates cortical actin reassembly via Rac
activation and leads to endothelial barrier enhancement,
whereas S1P3 activation in pulmonary epithelial cells leads to
disruption of tight junctions, possibly by activating Rho,
resulting in increased lung vascular permeability.59–61 The
role of S1P1 signaling in vascular maturation is demonstrated
by findings in S1P1 receptor null mice, which despite normal
angiogenesis die from intracranial hemorrhage at embryonic
day 12.5; deletion of the receptor prevents activation of the
small GTPase, Rac, which leads to failure in migration of
vascular smooth muscle cells and pericytes, a defect in
vascular maturation, and ultimately to hemorrhage.61
S1P AND IMMUNE CELLS
In circulating blood and lymph, S1P is generated predomi-
nantly by mononuclear phagocytes, activated mast cells, and
platelets.62,63 Intracellularly produced S1P is secreted and
then binds to albumin and other plasma proteins yielding high
concentrations of up to 5mM in extracellular compartments
compared to relatively lower concentrations in tissues. A high
level of S1P produced by SPHK elicits a variety of functional
responses in immune systems in a paracrine or autocrine
manner, depending on the expression pattern of S1PR
subtypes in immune cells (Table 1). Until recently, S1P–S1PR
signaling in immune cells has been examined mainly in
lymphocytes, mast cells, and dendritic cells (DCs).
In human and mouse CD4 and CD8 T cells, S1P1 and
S1P4 are the predominant S1PRs mediating the functional
responses to S1P.64 The effect of S1P on T-cell function
is concentration dependent. At low concentrations
(0.1–100 nM), S1P inhibits apoptosis and enhances chemo-
taxis to a variety of chemokines; at higher concentrations
(0.3–3 mM), S1P inhibits T-cell chemotaxis,65 an effect that is
mediated through S1P1 but not S1P4 receptors.
65 In addition,
S1P at a concentration range of 1 nM to 1 mM can inhibit CD4
T-cell proliferation and production of interferon-g and IL-4
without affecting IL-2.66 These multiple immune modulatory
functions of S1P are mediated through S1P1 activation.
66
S1P4 receptor activation also produces immunosuppression
by inhibiting T-cell proliferation and secretion of effector
cytokines, such as IL-2 or interferon-g, while enhancing
IL-10 secretion.67
Mast cells play an important role in innate and acquired
immunity and in allergic diseases by producing a variety of
vasoactive substances that increase vascular permeability and
leukocyte recruitment.68,69 Mast cells are also known to be an
important source of plasma S1P. Antigen-induced IgE
aggregation leads to activation of SPHK in mast cells, and
subsequent release of S1P into the extracellular space is
important in mast cell migration to the site of inflammation
and in the degranulation process.70–72 SPHK2 intrinsically
regulates mast cell calcium influx and responses, whereas
SPHK1 is important in regulating the levels of circulating S1P
and thus extrinsically affecting mast cell responsiveness.73
Elevated S1P levels have been detected in bronchoalveolar
lavage fluid of asthmatic patients.74 Mast cell-released S1P
Table 1 | S1P receptors in immune cells
Immune cell S1PR Functions
T cell S1P1 Decreased chemotaxis at low concentration
(0.1–100 nM) of S1P, increased chemotaxis at
high concentration (0.3–3 mM) of S1P, decreased
proliferation, decreased IFN-g and IL-4 secretion
S1P4 Decreased proliferation, decreased IFN-g and
IL-2 secretion, enhanced IL-10 secretion
B cell S1P1 Decreased chemotaxis at low concentration
(0.1–100 nM), increased chemotaxis at high
concentration (0.3–3 mM)
S1P4 Decreased proliferation
Mast cell S1P1 Increased chemotaxis, no effect on
degranulation
S1P2 Increased degranulation
Dendritic cell S1P1 Increased chemotaxis
S1P2 Decreased chemotaxis
S1P3 Migration to S1P
Macrophage S1P1 Increased chemotaxis
IFN-g, interferon-g; IL, interleukin; S1P, sphingosine-1-phosphate; S1PR, S1P receptor.
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Figure 2 | Sphingosine-1-phosphate (S1P) receptors. Intracellular
or extracellular sphingosine is phosphorylated by SPHK. S1P or
phosphorylated FTY720 in serum binds to specific members of the
S1PR family, which are coupled to different G proteins: EDG1/S1P1,
EDG5/S1P2, EDG3/S1P3, EDG6/S1P4, and EDG8/S1P5. SPH:
sphingosine, SPHK, sphingosine kinase, S1PP, sphingosine-1-
phosphate phosphatase, FTY720-P, phosphorylated FTY720.
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can transactivate S1P1 and S1P2 receptors in an autocrine
manner. S1P1 activation mediates mast cell migration
through cytoskeletal rearrangement, whereas S1P2 activation
inhibits chemotaxis primarily by downregulation of Rac
activity and activation of Rho.75,76 However, defects in
degranulation have been observed in bone marrow-derived
mast cells from S1P2-deficient mice or immortalized rat
basophilic leukemia cells transfected with antisense to S1P2,
whereas rat basophilic leukemia cells transfected with
antisense to S1P1 showed normal granule content despite
decreased chemotaxis, thus suggesting that S1P2 activation
mediates the degranulation process in mast cells.
DCs are antigen-presenting cells that link innate and
adaptive immune responses. In normal steady state, im-
mature DCs are present in virtually all tissues, participating
in immune surveillance. On antigenic stimuli, DCs undergo
maturational processing and migrate to draining lymph
nodes to activate the adaptive immune response. The
expression profile of S1PRs in mouse DCs varies with the
DC maturation status;77 mature DCs express higher levels of
S1P3 mRNA compared with immature DCs.
78 S1P binding to
S1PRs activates the small GTPase family, inducing migration
of DCs without affecting the maturation process.79 FTY720, a
nonspecific S1PR analog, can inhibit the migratory response
of mature DCs to S1P.79 On DC maturation, S1P increases
cytokine production from DCs leading to a Th2-dependent
response.80 Further evidence for the effects of S1P–SPHK
on DCs comes from the observation that S1P in a dose-
dependent manner (0.01–10 mM) significantly reduces the
percentage of apoptotic mature DCs and increases accumula-
tion of peripheral immature DCs at the location of antigen,
thereby facilitating subsequent antigen uptake.81 Further-
more, S1P regulates migration and endocytosis of mature
murine DCs via S1P3 but not S1P1.
78 These data suggest that
S1P signaling can be important in immune modulation
through effects on S1PRs expressed on DCs. Although some
aspects of immune cell regulation by S1P–S1PR signaling
have been clarified, the precise role of S1P in individual
immune cells or in the complex immune system still needs to
be investigated.
S1P EFFECTS ON LYMPHOCYTE TRAFFICKING
Naive T cells continuously circulate between blood and
lymphatic tissues as part of the immune surveillance system.
The lymphocyte homing process from blood into secondary
lymphoid organs via high endothelial venules depends on
various chemokines and signaling through their respective
receptors, such as CCL19 and CCL21 with CCR7, CXCL12
with CXCR4, and CXCL13 with CXCR5.82–84
Recent in vivo studies using FTY720, a novel immuno-
modulator, have clarified the mechanism of lymphocyte
egress from secondary lymphoid organs. FTY720, a sphingo-
sine analog, is activated in vivo by SPHK2 to form the active
principle, FTY720-P. FTY720-P, a structural analog of S1P,
binds to and activates four different S1PRs.85,86 Activation of
S1P1 receptors, for example, by FTY720-P, induces peripheral
lymphopenia by sequestering lymphocytes from blood and
spleen into secondary lymphoid organs,86–88 thereby suggest-
ing a role for S1P–S1P1 signaling in normal lymphocyte
trafficking. Infusion of S1P into the rat bloodstream also
evokes lymphopenia.86 In mice whose hematopoietic cells
lack S1P1 receptors, T cells are absent from peripheral blood
because of the inability of T cells to egress from the thymus.89
The observations that S1PR activation by S1P and FTY720-P
and the absence of S1PRs in lymphocytes derived from S1P1-
knockout mice both lead to blockade of lymphocyte egress
from secondary lymph organs seem incongruous at first
glance. This has been a controversial area in which two
hypotheses have been proposed. The first model is the
stromal-gate control model. In this model, S1P acts on ECs to
reduce the permeability of the endothelium in blood vessels
and lymphoid vascular sinuses, thereby preventing the
exodus of lymphocytes. The second model is referred to as
the S1P–S1P1 control-of-lymphocytes model. In this model,
FTY720 or S1P acts as ‘functional antagonist’ leading to the
downregulation of S1P1 receptors expressed on lymphocytes
rendering them unresponsive to a gradient of S1P level
(blood4lymphatic tissue).90 Recently, however, we and
others have demonstrated that selective S1P1 antagonists
including VPC44116 increase endothelial permeability and
do not induce lymphopenia,91,113 supporting the stromal-
gate control model. It may be that both models may
contribute variably to the lymphopenia observed with
FTY720. This finding establishes the intrinsic requirement
of lymphocyte S1P1 receptor in lymphocyte egress from
secondary lymphoid organs. S1P–S1P1 signaling in lympho-
cytes appears to be important in the adaptive immune
response because antigen-specific T cells in lymph nodes lose
their S1P responsiveness with transient downregulation of
S1P1 receptors shortly after antigenic challenge, thereby
permitting clonal expansion in lymph nodes. However,
several days later, antigen-specific T cells recover from
transient S1P unresponsiveness with S1P1 receptor expression
and re-entry into the peripheral circulation to produce
immune responsiveness. These findings support the associa-
tion of loss of S1P responsiveness with initial retention of
antigen-specific T cells and also the association of acquisition
of S1P responsiveness with their egress from lymph node,
confirming the role of lymphocyte S1P–S1P1 signaling in
lymphocyte trafficking.89,92 Failure to respond to S1P has also
been demonstrated in lymphocytes from FTY720-treated
animals. Lymphocytes from these FTY720-treated animals
showed almost complete downregulation of S1P1 receptors.
89
S1P EFFECTS ON CELL SURVIVAL
It is now clear that S1P is an extracellular ligand for specific
G-protein-coupled receptors that are implicated in a variety
of biological and pathological events. However, the following
lines of evidence suggest that S1P can also function as an
intracellular second messenger, although the intracellular
target of S1P has not yet been identified: (1) yeast does not
express S1PRs but still responds to S1P;93,94 (2) dihydro-S1P
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(sphinganine), a compound identical to S1P except that it
does not have a 4,5-trans double bond, can bind to and
activate all S1PRs, but cannot reproduce all the effects of S1P,
especially those associated with cell survival;7,95 (3) micro-
injection of S1P increases the level of intracellular S1P and
mobilizes calcium in a pertussis toxin-insensitive manner,
whereas extracellular S1P has no effect on calcium mobiliza-
tion.7,96,97
Although S1P enhances cell proliferation and survival,
ceramide and sphingosine, two precursors of S1P are
associated with cell growth arrest and apoptosis.10–13 An
increase in S1P level or decrease in ceramide can prevent
oocytes from radiation-induced apoptosis in wild-type mice.7
Similarly, pretreatment of human ECs with S1P protects
against early apoptosis, which was associated with an increase
in ceramide generation induced by radiation exposure;
however, no protection was noted with late apoptosis, which
was predominantly dependent on DNA damage.98 The
balance between sphingosine and S1P is decisive in mast cell
activation following FceR I activation.70,99 Because these
compounds are metabolically interconvertible, these results
suggest that the balance of proapoptotic ceramide and
sphingosine vs antiapoptotic S1P determines cell fate. More
importantly, these effects were neither blocked by pertussis
toxin nor reproduced by dimethyl sphingosine, indicating
that the cytoprotective effect of S1P is not S1PR-depen-
dent.29,31,100–102 Decreasing SPHK1 expression, the principal
enzyme in the generation of S1P, by small interfering RNA
induced cell cycle arrest and apoptosis in MCF-7 breast
cancer cell lines, suggesting an important role of endogenous
SPHK in cell survival.103 In addition, overexpression of
SPHK reduced apoptosis by inhibiting Jun N-terminal kinase
caspase activation.31 SPHK meditates ischemic precondition-
ing in murine heart.104 The protective effect of intracellular
S1P on cell survival is mediated in part by activation of
extracellular signal-regulated kinase 1/2, a stress-activated
protein kinase known to be associated with cell survival and
proliferation, and also via activation of the Akt–phosphatidyl
inositol-3-kinase pathway.105,106 Although these latter studies
did not explicitly demonstrate a receptor-independent
mechanism.104–106
Although many findings support the role of S1P as an
intracellular second messenger to promote cell survival and
proliferation, there are several recent reports demonstrating
that the prosurvival effect of S1P can also be mediated by
S1PRs. Extracellular S1P in nanomolar concentrations
inhibited cytokine-induced rat islet cell apoptosis, and this
effect was mimicked by dihydro-S1P and, more importantly,
was inhibited by the S1PR antagonist.20 In ECs, antisense
oligonucleotide to S1P1 or S1P3 receptor diminished the
protective effect of S1P on cell survival.107 Like the
intracellular S1P effects on cell survival, downstream
signaling events following these ligand–receptor interactions
also seem to involve extracellular signal-regulated kinase 1/2
activation or Ca-dependent pathways. Indeed, intracellular
S1P may be delivered extracellularly to activate G-protein-
coupled receptor-mediated cell survival pathways. Although
the mechanism of S1P’s export or inside-out signaling is not
known, ATP binding cassette (ABC) transporters in mast cells
may mediate S1P export.108 Inhibition of an ABC family
member (ABCC1) by either MK571, a selective inhibitor of
ABCC1, or antisense to ABCC1 mRNA blocked S1P
export.108 In contrast, inhibition of ABCB1 (P-glycoprotein)
did not block S1P export.108 These studies underscore the
complexity of S1P effects on cell survival. Evidence supports
both an intracellular and extracellular role of S1P in
mediating cell survival.
S1P EFFECTS ON ENDOTHELIAL AND EPITHELIAL BARRIERS
Cell barriers between different compartments are important
in normal physiology. The EC barrier separates circulating
vascular components from the interstitium, and disruption
of the EC barrier results in increased vascular permeability
with subsequent inflammation and organ dysfunction; in
neoplastic disease, this is accompanied by neoangiogenesis
and subsequent tumor metastasis. S1P maintains EC barrier
integrity primarily by binding to S1P1.
109,110 S1P1 is necessary
for maintaining the EC barrier; despite normal angiogenesis,
pericyte deficiency-induced incomplete vascular maturation
and intracranial hemorrhage result in embryonic lethality in
S1P1-knockout mice.
61 On the other hand, S1P1, S1P2, and
S1P3 receptors have a redundant or cooperative function for
development of a stable and mature vascular system during
embryonic development.111 S1P can induce a rapid increase
in transmonolayer electrical resistance in the pulmonary
microvascular endothelium, and this effect was markedly
reduced by S1P1 antisense oligonucleotide treatment.
112
Downstream signaling events following interaction of
S1P–S1P1 involve phosphatidyl inositol-3-kinase and Rac-1
activation with cortical actin rearrangement—events that
may be critical to maintain cellular architecture.59,112 Plasma
S1P acting on S1P1 receptors is important in maintaining
skin and lung capillary integrity. Vascular administration of
S1P1 antagonist reversed the protection from vascular
endothelial growth factor-induced leakage by selective S1P
agonist in skin. S1P1 antagonism also enhanced basal
pulmonary capillary leakage, and this was prevented by the
coadministration of S1P1 agonist.
113 Involvement of S1P2 in
endothelial permeability has also been demonstrated.
Activation of S1P1 receptors expressed on EC is important
in reducing permeability, hence maintaining the integrity of
vascular EC barrier function, whereas S1P2 receptor activa-
tion has the opposite effect. Activation of S1P2 in ECs
resulted in Rho-ROCK- and PTEN-dependent disruption of
adherens junctions, stimulation of stress fibers, and increased
paracellular permeability.114 JTE013, a selective S1P2 antago-
nist, improved endothelial barrier integrity. These data
provide evidence that the balance of S1P1 and S1P2 receptor
activities regulates vascular permeability by S1P.
Human ECs also express S1P3 in addition to S1P1
receptors; however, the role of S1P3 in endothelial barrier
function has not been fully demonstrated. S1P–S1P1 signaling
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couples to the Gi pathway with subsequent Rac activation,
whereas S1P–S1P3 signaling has been known to couple to Gi,
Gq/11, and G12/13 pathways and activate Rho GTPase instead
of Rac GTPase. Rho GTPases mediate endothelial dysfunc-
tion and abnormal smooth muscle cell proliferation and
are implicated in several diseases such as hypertension,
atherosclerosis, vascular spasm, and bronchial asthma.115,116
Consistent with the known function of Rho GTPase,
silencing S1P3 by small interfering RNA enhanced the
transmonolayer electrical resistance and cortical actin,
suggesting that S1P3 functions as a negative regulator of
S1P-induced endothelial barrier enhancement.117
Polarized epithelial cells form barriers that regulate the
vectorial transport of various ions and solutes. In contrast
to the barrier-enhancing effect of S1P–S1P1 signaling in
endothelium, less is known about the role of S1P in epithelial
barrier function. However, a recent study suggests the
importance of S1P3 receptors in lung epithelial barrier
disruption.60 Intratracheal but not intravenous delivery of
S1P induced acute pulmonary edema with disruption of tight
junctions in wild-type but not in S1P3 null mice. However,
the role of S1P–S1PR signaling in other epithelial cell types or
subsequent downstream signaling processes that mediate
epithelial barrier disruption has not been demonstrated and
needs to be elucidated.
S1P DRUG DEVELOPMENT
Before the realization that FTY720 is a prodrug and that the
active form, phospho-FTY720, is an S1PR agonist, predic-
tions of a useful S1PR drug centered on antagonists and,
more recently, on SPHK inhibitors—the reasoning being that
interdiction of the prosurvival, proangiogenesis functions of
S1P could be valuable in the setting of neoplastic disease.118
The paucity of useful S1PR antagonists has heretofore
prevented this idea from being tested in vivo. However, the
recent demonstration that administration of an S1P1
antagonist resulted in increased vascular permeability,91,113
presumably by interfering with endogenous S1P tone,
suggests that S1P1 antagonists as a class might have a toxic
liability. The utility, if any, of S1PR antagonists selective for
other S1PR types awaits the development of such agents.
As mentioned previously, phospho-FTY720, acting as an
agonist at lymphocyte S1P1 receptors, evokes a long-lasting
lymphopenia that is the result of disruption of normal
lymphocyte trafficking from the secondary lymphoid tissue.
(Curiously, S1P1 receptor antagonists do not affect circulat-
ing lymphocyte levels (see above),91,113 which suggests a lack
of endogenous S1P tone on lymphocyte trafficking.) An
explanation commonly offered to explain the efficacy of
FTY720 in transplantation and autoimmune disease models
is that by trapping lymphocytes in lymphoid tissues, effector
T lymphocytes are directed away from sites of inflammation
and allografts. However, FTY720 also causes a transient
bradycardia in experimental animals and humans. In rodents,
the bradycardia results from agonist activity at the S1P3
receptor. These twin observations have prompted a search for
S1P1 receptor-selective agonists, and the screening of
complex chemical libraries has apparently yielded a rich vein
of such compounds. Although FTY720-dependent decrease
in atherosclerosis was demonstrated,119 a fundamental, but as
yet unanswered, question is whether efficacy of the non-
selective FTY720 in a variety of disease models such as
atherosclerosis can be duplicated by more selective agents. An
early example of such an S1P1-selective compound is
SEW2871, which is structurally not related to sphingosine
or FTY720. The scrutiny that the pharmaceutical industry
is giving to S1P signaling will address whether more
selective novel compounds have a similar efficacy to
FTY720. Table 2 lists currently available S1P compounds
and their sources.
S1P AND KIDNEY DISEASE
The biological functions of S1P have been explored in diverse
cell types and tissues. However, the exact role of S1P in
kidney physiology and pathophysiology remains unclear.
S1P1 receptors are expressed in the kidney
129 and play an
important role in maintaining EC integrity57,130 and in
trafficking of lymphocytes.3 Recently, we demonstrated
expression of S1P14 receptors in whole mouse kidneys with
a rank order of S1P14S1P34S1P24S1P4, whereas S1P5
mRNA was not found.131 Cultured mesangial cells also
express S1P15 receptors.
132 However, whether the corre-
sponding receptor subtypes are expressed at the protein level
has not been investigated because of lack of antibodies.
The therapeutic relevance of S1P as a target in kidney
disease has been explored with FTY720. FTY720 prolonged
allograft survival in animal solid organ transplantation
models,133,134 mainly by eliciting lymphopenia resulting
from a reversible redistribution of lymphocytes from the
circulation to secondary lymphatic tissue. However, a recent
phase III clinical trial using 2.5 or 5 mg of FTY720 failed to
demonstrate an improvement in efficacy for the prevention
of renal allograft rejection when combined with cyclosporine
and mycophenylate. FTY720 (5 mg) combined with a
reduced dose of cyclosporine was discontinued because of
increased incidence of acute rejection and, more importantly,
because FTY720 was associated with significantly lower
creatinine clearance and several unexpected side effects that
need to be further investigated.135
S1P IN RENAL ISCHEMIA–REPERFUSION INJURY
The mechanisms involved in renal ischemia–reperfusion
injury (IRI) are complex,136,137 and both innate and adaptive
immunity play a prominent role.138,139 Following IRI, ECs
and tissue-resident leukocytes are activated, leading to
leukocyte infiltration.139 Bone marrow-derived cells are
important in mediating injury associated with IRI.140
Neutrophil infiltration of kidneys subjected to IR is
associated with injury.136,139,141–144 More recent studies
support the role of macrophages145,146 and T cells in the
early antigen-independent inflammatory response following
reperfusion.143,147,148
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Troncoso et al.149 demonstrated that FTY720 is protective
following kidney IRI. We confirmed these observations and
provided data on the optimal dose of FTY720 that confers
renal tissue protection after IRI. The tissue-protective effect
of FTY720 was associated with a decrease in lymphocyte,
macrophage, and neutrophil infiltration into postischemic
kidney, a result consistent with the prevailing view that
inflammatory cell infiltration appears to play an important
role in the pathogenesis of IRI.139,142,150 Loss of significant
protection from IRI with the highest doses of FTY720
suggested the possibility that S1PR subtypes may have
opposing and/or different functional effects.
Using selective agonists and antagonists, we further
demonstrated that the protective effect of FTY720 is due
primarily to activation of S1P1 receptors. Administration of
VPC44116, a selective S1P1 receptor antagonist, reversed
FTY720-induced protective effects. Interestingly, the effect of
VPC44116 in blocking FTY720 was not associated with
reversal of lymphopenia induced by FTY720 treatment. The
finding that VPC44116 blocked the protective effect of
FTY720 suggests that FTY720-mediated protection is not
consistent with the concept of FTY720-induced ‘functional
antagonism.’ The possibility that FTY720 may have addi-
tional effects independent of lymphocytes cannot be
excluded. Furthermore, the protective effect of FTY720 is
mimicked by SEW2871, a selective S1P1 agonist. SEW2871
induces renal tissue protection after IRI by inhibiting
lymphocyte egress and reducing levels of the proinflamma-
tory molecules tumor necrosis factor-a, P-selectin, and
intercellular adhesion molecule-1.151 Whether the protective
effect of FTY720 is due to the action on immune cells and/or
kidney cells is not clear. However, a pronounced increase in
S1P1 mRNA expression occurring far before the peak of
kidney leukocyte infiltration suggests a possible role of
kidney tissue S1P1 receptor activation that could be
important in renal tissue protection. Activation of S1P1
receptors on DCs reduces IL-12 and IL-10 production.152 IL-
12 activates natural killer T cells,153 which contribute
importantly to the innate immune system. IL-10 is a potent
anti-inflammatory cytokine and has been shown to protect
kidneys from acute injury.154 S1P1 receptor activation in
vascular ECs is implicated in angiogenesis, cell proliferation,
stimulation of EC nitric oxide synthase enzyme,57 and
reduction of monocyte adhesion.155 These effects on ECs
may lead to maintenance of endothelial barrier function.156
Our data confirm this hypothesis and show a beneficial effect
of FTY720 to reduce vascular permeability following renal
IRI.131 Whether the effect of FTY720 to preserve vascular
permeability is due to a direct effect on ECs or due to an
indirect effect through immune cells is not certain. The
possible involvement of other S1PR subtypes by high doses of
FTY720 is not clear in this study and needs to be explored.
FTY720 also reduced cyclosporine A nephrotoxicity, and this
protective effect was accompanied by reduced lymphocyte
and macrophage infiltration and fibrosis.157 The protective
effect of FTY720 in a chronic kidney disease model, such as
diabetic nephropathy, needs to be further explored, and it
might provide a new therapeutic tool in retarding the
progression of kidney disease.
S1P IN KIDNEY MESANGIAL CELLS
Mesangial cells play a key role in the pathogenesis of many
kidney diseases such as glomerulonephritis or diabetic
nephropathy by producing profibrotic cytokines and/or
inducing extracellular matrix protein accumulation. S1P
stimulates the proliferation of mesangial cells by activating
Table 2 | S1P compounds
Compound Activity Reference Commercial source
FTY720a S1P1,3,4,5 agonist Kiuchi et al.
120 Cayman Chemical
AAL149, AAL151b S1P1,3,4,5 agonist Brinkmann et al.
85 None
SEW2817c S1P1 agonist Sanna et al.
121 Sigma-Aldrich
Compound 26d S1P1 agonist Li et al.
122 None
VPC01091e S1P1,4,5 agonist, S1P3 antagonist Zhu et al.
123 None
JTE013 S1P2 antagonist Ohmori et al.
124 Tocris
VPC23019 S1P1,3 antagonist
f Davis et al.125 Avanti Polar Lipids
VPC44116 S1P1,3 antagonist
g Foss et al.91 None
S1P (R isomer)h S1P1 antagonist Sanna et al.
113 Avanti Polar Lipids
N,N-dimethylsphingosinei SPHK inhibitorj Yatomi et al.126 Avanti, others
Compounds II, IVk SPHK inhibitor French et al.127 Sigma-Aldrich
2-acetyl-4-tetrahydroxybutylimidazole (THI) S1P lyase inhibitor Schwab et al.128 None
S1P, sphingosine-1-phosphate; SPHK, sphingosine kinase.
aOrally available prodrug, receptor active form is phospho-FTY720, Kd at S1P1o1 nM.
bEnantiomers of a FTY720 analog, only AAL151 is activated by SPHK2.
cOrally available, ca. 2 log orders less potent than FTY720.
dOrally available, more potent than SEW2871.
eOrally available prodrug, FTY720 analog, very long lasting in vivo, selective SPHK2 substrate.
fTen-fold more potent at S1P1 receptor (Ki 30 nM) than S1P3 receptor, very short lived in vivo.
gPhosphonate analog of VPC23019, T1/2 in rats 3.1 h.
hPhosphonate analog of VPC23019.
iVery low potency at some sphingosine kinase types.
jNote that, unlike S1P receptors, sphingosine kinases differ widely among mammalian species, thus claims for inhibition should not be extrapolated to other species.
kWe have been unable to verify claims for inhibitory activity of compound II in recombinant mouse or human sphingosine kinases.
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extracellular signal-regulated kinase 1/2 pathways. The
suppression of endogenous S1P2 and S1P3 by antisense
oligonucleotides reduced the antiapoptotic effects of S1P,
indicating that the antiapoptotic effect of S1P is mediated by
S1P2 and S1P3 receptors in mesangial cells.
158 Mesangial cell
S1P3 activation also mediates transforming growth factor-b
and Smad protein activation by FTY720 with upregulation of
connective tissue growth factor and collagen.159 This study
suggests that S1PR signaling in mesangial cells can be
associated with fibrotic processes and progression of chronic
kidney disease and needs to be further clarified in future
studies.
CONCLUSION
S1P, through intracellular and extracellular effects, governs a
number of cellular processes that determine cell fate. S1P acts
as an intracellular mediator that counterbalances the effects
of sphingosine and ceramide. The balance between these
signaling mediators ultimately determines cell fate. In
addition, S1P is a classic ligand for five membrane-bound
G-protein-coupled receptor subtypes. The unique tissue
distribution of the receptor subtypes and the differing
signaling pathways and downstream cellular effects resulting
from S1PR subtype activation underscore the need for
discovery and testing of novel subtype-specific S1PR
compounds for the treatment of a variety of disorders.
Currently, S1PR compounds are being used in clinical trials
for multiple sclerosis and in preclinical studies for a number
of different disorders. Given the importance of the immune
system in kidney disease, S1PR compounds hold great
promise for the treatment of various kidney disorders. The
treatment of acute kidney injury is an important priority
given the high morbidity and mortality associated with this
disorder and its less-recognized contribution to the pre-
valence of end-stage renal disease. S1PR analogs appear to be
particularly attractive for the treatment of acute kidney
injury.
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